- Afimoxifene
Chembox new
ImageFile= Afimoxifene.png
IUPACName=("Z")-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
OtherNames=4-hydroxytamoxifen
Section1= Chembox Identifiers
CASNo=68392-35-8
PubChem=449459
SMILES=CCC(c1ccccc1)=C(c2ccc(OCCN(C)C)cc2)/c3ccc(O)cc3
Section2= Chembox Properties
Formula=C26H29NO2
MolarMass=387.51396
Appearance=
Density=
MeltingPt=
BoilingPt=
Solubility=
Section3= Chembox Hazards
MainHazards=
FlashPt=
Autoignition=Afimoxifenecite web | url = http://www.ama-assn.org/ama1/pub/upload/mm/365/afimoxifene.pdf | title = Statement on a nonproprietary name adopted by the USAN council: Afimoxifene | accessdate = 2008-03-26 | author = | authorlink = | coauthors = | date = | format = | work = | publisher = American Medical Association | pages = | language = | archiveurl = | archivedate = | quote = ] is a
selective estrogen receptor modulator whose active ingredient is 4-hydroxytamoxifen which is identical to the activemetabolite oftamoxifen .cite journal |author=Desta Z, Ward BA, Soukhova NV, Flockhart DA|title=Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6|journal= J Pharmacol Exp Ther |volume= 310 |issue= 3 |pages= 1062–75 |year= 2004 | doi = 10.1124/jpet.104.065607 |pmid= 15159443] Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel. Afimoxifene has completed a phase II clinical trial for the treatment of cyclicalmastalgia .cite journal | author = Mansel R, Goyal A, Nestour EL, Masini-Etévé V, O'Connell K | title = A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women | journal = Breast Cancer Res. Treat. | volume = 106 | issue = 3 | pages = 389–97 | year = 2007 | pmid = 17351746 | doi = 10.1007/s10549-007-9507-x | issn = ]References
External links
*MeshName|4-hydroxytamoxifen
Wikimedia Foundation. 2010.
